Preclinical and clinical research success in drug development increasingly depends on the performance of contract research organizations (CROs). Yet identifying, selecting, negotiating, and coordinating the activities of bioanalytical services, preclinical safety evaluation, formulation development, clinic-ready manufacturing, clinical conduct and more among multiple CROs can be a tricky thread-the-needle process.

How can you speed development with minimal negotiation, deadline and technology transfer conflicts and delays? A new playbook examines CRO and contract development and manufacturing organizations (CDMO) success factors, offering biopharma leaders insights and solutions to accelerate go-to-market results, plus:

• What to look for – and look out for – in the CRO selection process
• Why CRO size and service capability should factor heavily in partner selection 
• What the survey findings of 143 biopharma executive reveal about CRO challenges and opportunities

​